Supernus Pharmaceuticals (SUPN) Amortization - Intangibles (2019 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Amortization - Intangibles of $25.3 million for Q2 2026, up 21.68% year-over-year from $20.8 million in Q2 2025, and up 3.11% on a QoQ basis from $24.6 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Amortization - Intangibles (2019 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Amortization - Intangibles for 8 years, with the latest figure at $25.3 million in Q2 2026.
- Amortization - Intangibles for Q2 2026 came in at $25.3 million, up 21.68% year-over-year; the trailing twelve-month figure through Jun 2026 was $95.0 million (up 21.26% YoY), and the FY2025 annual result was $89.5 million, up 14.74% from the prior year.
- Amortization - Intangibles improved to $25.3 million in Q2 2026, from $24.6 million in the prior quarter.
- Over five years, Amortization - Intangibles peaked at $25.3 million in Q2 2026 and troughed at $18.3 million in Q4 2024.
- A 5-year average of $21.1 million and a median of $20.6 million in 2022 frame the typical range for Amortization - Intangibles.
- The widest annual swing landed in 2022, when Amortization - Intangibles jumped 247.07%; it then dropped 13.36% in 2024.
- A 5-year view of Amortization - Intangibles shows it stood at $20.7 million in 2022, then advanced by 1.86% to $21.1 million in 2023, then dropped by 13.36% to $18.3 million in 2024, then soared by 34.5% to $24.6 million in 2025, then advanced by 3.11% to $25.3 million in 2026.
- Per Business Quant data, the three most recent Amortization - Intangibles figures were $25.3 million in Q2 2026, $24.6 million in Q4 2025, and $24.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.76 Bn | 2.39 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.33 Mn |
| Dec 31, 2025 | 24.56 Mn |
| Sep 30, 2025 | 24.33 Mn |
| Jun 30, 2025 | 20.80 Mn |
| Mar 31, 2025 | 19.79 Mn |
| Dec 31, 2024 | 18.24 Mn |
| Sep 30, 2024 | 19.50 Mn |
| Jun 30, 2024 | 20.10 Mn |
| Mar 31, 2024 | 20.10 Mn |
| Dec 31, 2023 | 21.08 Mn |
| Sep 30, 2023 | 21.24 Mn |
| Jun 30, 2023 | 20.10 Mn |
| Mar 31, 2023 | 19.97 Mn |
| Dec 31, 2022 | 20.73 Mn |
| Sep 30, 2022 | 20.64 Mn |
| Jun 30, 2022 | 20.64 Mn |
| Mar 31, 2022 | 20.64 Mn |
| Dec 31, 2021 | 12.03 Mn |
| Sep 30, 2021 | 6.01 Mn |
| Jun 30, 2021 | 5.95 Mn |